No quarterly revenue total was found in Corvus Pharmaceuticals, Inc.'s SEC filings.
Corvus Pharmaceuticals, Inc. (CRVS) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$12.3 million. As of Sep 30, 2026 it held $202.9 million in cash and investments and $632,000 in total debt.
Revenue
—
Net income
$-20.34M
-100.3% vs year-ago quarter
Operating cash flow
$-12.21M
-27.7% vs year-ago quarter
Free cash flow
$-12.28M
-28.4% vs year-ago quarter
EPS
$-0.22
-83.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
84.35M
+12.9% vs year-ago quarter
Net cash
$202.31M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CRVS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1626971
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$21.4M | -$19.3M | -$14.9M | -$12.2M | -$10.6M |
| Net income | -$20.3M | -$18.0M | -$13.7M | -$12.3M | -$10.2M |
| Diluted EPS | -$0.22 | -$0.19 | -$0.15 | -$0.15 | -$0.12 |
| Operating cash flow | -$12.2M | -$15.4M | -$10.4M | -$9.2M | -$9.6M |
| Free cash flow | -$12.3M | -$16.0M | -$10.5M | -$9.2M | -$9.6M |
| Total assets | $223.9M | $239.3M | $253.2M | $71.1M | $80.5M |
| Total liabilities | $15.6M | $13.9M | $12.5M | $9.9M | $8.7M |
| Stockholders' equity | $208.3M | $225.3M | $240.7M | $61.2M | $71.8M |
| Cash and investments | $202.9M | $215.2M | $236.7M | $56.8M | $65.7M |
| Total debt | $632,000 | $728,000 | $834,000 | $937,000 | $1.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 22, 2026 | Jul 21, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 11, 2026 |
All 583 Corvus Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.